Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1(MN) gp120, HIV-1(SF2) recombinant gp120, or both vaccines in seronegative adults

Journal of Infectious Diseases

Volumn 177, Issue 5, 1998, Pages 1230-1246

  Clements Mann, Mary Lou ^a   Weinhold, Kent ^b   Matthews, Thomas J ^b   Graham, Barney S ^b   Gorse, Geoffrey J ^b   Keefer, Michael C ^b   Juliana McElrath, M ^b   Hsieh, Ray Hahn ^b   Mestecky, Jiri ^b   Zolla Pazner, Susan ^b   Mascola, John ^b   Schwartz, David ^b   Siliciano, Robert ^b   Corey, Lawrence ^b   Wright, Peter F ^b   Belshe, Robert ^b   Dolin, Raphael ^b   Jackson, Susan ^b   Xu, Serena ^b   Fast, Patricia ^b   Walker, Mary Clare ^b   Stablein, Don ^b   Excler, Jean Louis ^b   Tartaglia, James ^b   Duliege, Anne Marie ^b   Sinangil, Faruk ^b   Paoletti, Enzo ^b   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT GLYCOPROTEIN GP 120; RECOMBINANT GLYCOPROTEIN GP 160; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS RNA; VIRUS VECTOR;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ARTICLE; CANARYPOX VIRUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MIGRAINE; MULTICENTER STUDY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RABIES VIRUS; RANDOMIZED CONTROLLED TRIAL; VIRUS EXPRESSION; VIRUS NEUTRALIZATION;

EID: 7144259087     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515288     Document Type: Article

References (13)

1. Global overview: a powerful HIV/AIDS pandemic. AIDS in the world. In: Mann J, Tarantola D, eds. Status and trends of the HIV/AIDS pandemic. New York: Oxford University Press, 1996.
2. Zagury D, Bernard J, Cheynier R, et al. A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS. Nature 1988;332:728-31.
3. Picard O, Achour A, Bernard J, et al. A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunity. J Acquir Immune Defic Syndr 1992;5:539-46.
4. Cooney EL, McElrath MJ, Corey L, et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA 1993;90:1882-6.
5. Graham BS, Matthews TJ, Belshe RB, et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J Infect Dis 1993;167:533-7.
6. Graham BS, Gorse GJ, Schwartz DH, et al. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. J Infect Dis 1994;170: 782-6.
7. Baxby D, Paoletti E. Potential use of nonreplicating vectors as recombinant vaccines. Vaccine 1992;10:8-9.
8. Cadoz M, Strady A, Meignier B, et al. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 1992;339:1429-32.
9. Fries LF, Tartaglia J, Taylor J, et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 1996;14:428-34.
10. Taylor J, Weinberg R, Tartaglia J, et al. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 1992; 187:321-8.
11. Pialoux G, Excler JL, Riviere Y, et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MM) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res Hum Retroviruses 1995;11:373-81.
12. Taylor J, Trimarchi C, Weinberg R, et al. Efficacy studies on a canarypoxrabies recombinant virus. Vaccine 1991;9:190-3.
13. Taylor J, Meignier B, Tartaglia J, et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65), in non-avian species. Vaccine 1995;13:539-49.